Clinical trials: Normal Skin
Hypersensitivity, Immediate, Autoinflammatory Syndromes
Pathogenesis of Physical Induced Urticarial Syndromes
Background: Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria).
- Conditions
- Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
- Trial name
- NCT00887939
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Breast Cancer
How Breast Conservative Surgery (BCS) Affects Women's Daily Activities On Post-Operation 2 Days?
we revise 8 disability items from SPADI into Chinese to develop a simple self-completion questionnaire for the assessment of restriction in daily activities resulting from breast conservative surgery.
- Trial name
- NCT00265213
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Mucopolysaccharidosis III-B
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
- Trial name
- NCT06488924
- Testing
- JR-446
- Where
- 4 sites in Japan
- Volunteers
- 10 people
- Sponsor
- JCR Pharmaceuticals Co., Ltd.
Primary; Complex, Pigmented Nodular Adrenocortical Disease, Primary, 1
Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)
Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed.
- Conditions
- Primary; Complex, Pigmented Nodular Adrenocortical Disease, Primary, 1, Periorificial Lentiginosis, Cardiac Myxoma
- Trial name
- EVACARNEY (NCT00668291)
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis and prevent…
- Trial name
- NCT00480610
- Testing
- tacrolimus ointment
- Where
- 22 sites in Austria, Belgium and 11 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc
Herpes Simplex Virus Infection, Varicella Zoster Virus Infection
Pharmacokinetics of Valacyclovir Oral Solution in Children
Valacyclovir has replaced acyclovir in many clinical scenarios. Pharmacokinetic data support the use of oral valacyclovir in children, but practical problems exist in children having to take adult-dose tablets.
- Trial name
- VALID2 (NCT04081480)
- Testing
- Valacyclovir
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Radboud University Medical Center
Acne Vulgaris
Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel
This pilot study will explore if continuation of treatment of treatment with Aczone 5% gel following combination treatment with with doxycycline and Aczone 5% gel can maintain therapeutic response.
- Trial name
- NCT01885910
- Testing
- Doxycycline 100mg, Aczone 5% gel
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)
This study will gather information on the safety and efficacy of patients with rheumatoid arthritis (RA) who are starting treatment with infliximab for the first time.
- Trial name
- NCT00724243
- Testing
- Infliximab
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Sunburn
Clinical Safety Trial of Long-Term Intermittent Use of Helioblock® SX Cream
The purpose of this study is to determine the safety potential of Helioblock® SX Cream as a sunscreen product in long term intermittent use conditions among pediatric subjects..
- Trial name
- NCT00326274
- Testing
- Helioblock® SX Cream
- Where
- United States
- Sponsor
- Loreal USA
Port Wine Stain
The Role of Angiogenesis-related Pathways in the Development of Port Wine Stains
1. Port wine stain (PWS) is a congenital, progressive vascular malformation of human skin involving the superficial vascular plexus that occurs in estimated 3-5 children per 1,000 live births.
- Trial name
- NCT03948997
- Testing
- Pulsed dye laser (PDL)
- Volunteers
- 80 people
- Sponsor
- xjpfW
Juvenile Idiopathic Arthritis
Interleukin 33 in Juvenile Idiopathic Arthritis Patients
The aim of this study is to measure serum and synovial fluid levels of IL 33 and its relative mRNA expression in peripheral blood mononuclear cells in juvenile idiopathic arthritis (JIA) patients and to correlate it with the…
- Trial name
- NCT03835624
- Testing
- interleukin 33
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Benha University
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Mucopolysaccharidosis I, Hurler's Syndrome
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.
- Conditions
- Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie's Syndrome
- Trial name
- NCT00144768
- Testing
- laronidase
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Early Breast Cancer
Electronic Study for Anastrozole Pharmacovigilance Evaluation
Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer
- Trial name
- E-SAFE (NCT00558168)
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Acne
Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
- Trial name
- NCT01243450
- Testing
- Tretinoin
- Where
- United States
- Volunteers
- 958 people, healthy volunteers welcome
- Sponsor
- Spear Pharmaceuticals
Tinea Corporis
Pediatric Subjects With Tinea Corporis
The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm).
- Trial name
- NCT02227290
- Testing
- Naftin Cream
- Where
- 19 sites in United States, Dominican Republic and 3 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Leishmaniasis, Cutaneous
Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)
The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).
- Trial name
- NCT01032382
- Testing
- WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream), Paromomycin Alone Cream (15% paromomycin topical cream)
- Where
- Peru
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Skin Barrier to Water Loss, Skin Health
Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery
This clinical study evaluates a topical botanical formulation for supporting skin recovery following invasive and non-invasive aesthetic procedures.
- Conditions
- Skin Barrier to Water Loss, Skin Health, Skin Discoloration, Skin Irritation
- Trial name
- APC-SKIN (NCT07807085)
- Testing
- Apple Peptide Complex Post-Aesthetic Care Protocol
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Grow Out Oils Clinical Aromatherapy Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.